ADVANCE: Anticancer Dark RNA Vaccines
In ADVANCE, five European partners are developing an RNA vaccine against liver cancer. The vaccine targets a hidden source of targets: small 'dark' proteins that are only made in cancer cells. The Princess Máxima Center leads the search for these targets together with Goethe University Frankfurt. The techniques we use and develop for this are also applicable to childhood cancers. Like liver cancer, these often have few mutations, which makes them hard to treat with immunotherapy.
What is the project about?
Liver cancer is usually detected late, when it responds poorly to treatment, including immunotherapy. A vaccine can help the immune system recognise the tumour. This requires targets that are only present on cancer cells, and because liver cancer has few mutations, there are few of them. ADVANCE therefore looks for them in the 'dark' proteome: small proteins made from stretches of DNA that were long considered non-coding. The goal is a first RNA vaccine against these targets, packaged in lipid nanoparticles, with its effect demonstrated in the lab and in mouse models.
Our role
Together with Goethe University Frankfurt, the Princess Máxima Center’s Van Heesch research group leads the first part of the project: finding the targets. Using Ribo-seq, we map which dark proteins are actually made in liver cancer cells and tumour tissue. Together with the partners, we then select the targets that are truly specific to the tumour and absent from healthy tissue. The other partners use this selection to design, produce and test the vaccine.
What makes ADVANCE unique?
ADVANCE focuses on a layer of targets that current vaccines do not use. The project also investigates whether existing drugs that put tumour cells under stress, such as sorafenib, make more of these targets visible and increase how many patients share the same targets. All data collected will feed an AI tool that predicts, per patient, which targets belong in a personalised vaccine.
Why it matters for the Máxima
Many childhood cancers also have few mutations. Dark proteins as targets for immunotherapy are a key focus of our childhood cancer research. ADVANCE strengthens the techniques and knowledge we need for this, and shows how to get from such a target to a vaccine.
The project at a glance
ADVANCE is a four-year EIC Pathfinder project. The consortium consists of five partners from three countries: three research institutes, a university and a biotech company. The coordinator is CIMA (University of Navarra) in Pamplona, Spain. The Máxima is a partner.
Partners
• Fundación para la Investigación Médica Aplicada (FIMA/CIMA), Spain (coordinator)
• Goethe University Frankfurt, Germany
• Princess Máxima Center for Pediatric Oncology, Netherlands
• Certest Biotec, Spain
• Netherlands Cancer Institute (NKI), Netherlands
Contact

Sebastiaan van Heesch
Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Innovation Council and SMEs Executive Agency (EISMEA). Neither the European Union nor the granting authority can be held responsible for them.